ReShape Lifesciences™ Continues Momentum of Direct-to-Consumer Marketing Campaign… | Your money

The next generation of patients are engaged, as evidenced by increased website traffic and physician referrals

Bariatric surgeons are seeing an increase in patient consultations and procedures

Insurance coverage continues to improve for bariatric procedures

SAN CLEMENTE, Calif., March 24, 2022 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the leading physician-led weight loss and metabolic health solutions company, today announced the continued momentum of its nationwide direct-to-consumer (DTC) campaign, which has led to a substantial increase in visits to lapband.compatients requesting additional information and scheduled medical consultations.

Since the start of the marketing campaign, in October 2021, the Company has recorded 250,000 additional patient visits to the website, lapband.com, resulting in more than 900% more patient inquiries about the Lap-Band® procedure, compared to the pre-launch DTC marketing campaign. Importantly, physician referrals for consultations have also increased by nearly 400%1.

*See disclaimer below

See our Lap-Band TV commercials here: https://www.reshapelifesciences.com/lapbandvideos/.

“The success at this stage of our DTC marketing campaign has led to a significant increase in potential engagement from bariatric patients and surgeons, indicating that our message is clearly resonating with both consumer and professional markets,” said said Bart Bandy, CEO and President of ReShape. Life Sciences™. “We recognize that the process and mandatory 4-6 month insurer waiting periods represent a disconnect between early engagement and procedures, but these early metrics and typical conversion rates are extremely promising as we have seen a 25% increase in requests from bariatric practices for upgrading and certification on the Lap-Band procedure. Additionally, traffic to our surgeon locator increased by 1,300% compared to the pre-launch of the DTC marketing campaign, with bariatric surgeons reporting an increase in direct practice calls and consultations.

Surgeon’s comments:

“ReShape’s recent interest in Lap-Band is helping me get through COVID. I’m scheduling these patients as fast as I can” – Georgia “I’ve had more Lap-Band consultations in the past two months than I ‘had some in 2021’ – Utah ‘62% of hot transfers have already been scheduled for consultations’ – Indiana

“The above testimonials represent real evidence of the success of our marketing campaign, which should continue to promote increased demand for Lap-Band procedures and, therefore, a potentially significant increase in ReShape’s revenue. It is also important to note that recent market pressure has caused several insurers to reduce these mandatory waiting periods and that 23 states now require bariatric surgery to be included in all individual, family and small group insurance plans. , which further ensures that more patients will be reimbursed. for our safe and effective weight loss solution,” concluded Mr. Bandy.

Throughout March, the Lap-Band is featured in ten major publications and over 20 national cable channels. The company also engages in other cooperative marketing partnerships, local digital media and a national social media influencer campaign.

The Lap-Band, manufactured by ReShape Lifesciences, has been used over a million times worldwide in bariatric surgery. The Lap-Band is clinically proven to be the safest bariatric procedure available on the market, backed by over 20 years of data demonstrating lower complication and mortality rates than other surgical weight loss procedures2. It is also FDA approved for specific indications and reimbursed by most insurance companies.

About ReShape Lifesciences™ ReShape Lifesciences™ is America’s leading weight loss and metabolic health solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® program provides a long-term, minimally invasive treatment for obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the US) minimally invasive medical device implanted via laparoscopy that wraps around the stomach, mimicking the gastric volume reduction effect of conventional weight loss surgery . It helps to enable rapid weight loss in obese and morbidly obese patients without permanently altering the patient’s anatomy. reshapecare™ is a virtual weight management program that supports lifestyle changes for all weight loss patients led by certified health coaches to help them maintain weight over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products for all consumers to help them achieve their health goals. For more information, please visit www.reshapelifesciences.com

* National Cable TV logos used in this press release are trademarks of the respective stations. National Print Magazine logos used in this press release are trademarks of their respective publishers.

1 Percentage increase in campaign performance compares the daily average of the pre-launch baseline (January – April 2021) to the daily average of the post-launch (Oct. 2021 – Feb. 2022). Data on file. ReShape Lifesciences Inc.

2 LAGB has lower morbidity, readmission, and risk-adjusted reoperation/intervention rates than LSG and LRYGB/ORYGB. Source: Hutter M., Schirmer B., Jones D., Ko C., Coher M., Merkow R., Nguyen N., First Report of the American College of Surgeons – Network of Bariatric Surgery Centers: Laparoscopic Gastrectomy in sleeve has morbidity and efficiency Positioned between band and bypass, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339264/ The following source describes sleeve gastrectomy as the removal of 80% of the stomach: ASMBS Bariatric Surgery Procedures: Sleeve Gastrectomy: https://asmbs.org/patients/bariatric-surgery-procedures#sleeve The following source describes how gastric bypass surgery uses hundreds of staples in the procedure that shrinks the size of the stomach and redirects the small intestine and digestive tract: Gastric Bypass Surgery | MedlinePlus [Online]. Available: https://medlineplus.gov/ency/article/007199.htm. [Accessed: December 13, 2016].

Safe Harbor Forward-Looking Statement: This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by the use of words such as “expect” , “plan”, “anticipate”, “could”, “may”, “intend”, “will”, “continue”, “future”, other words of similar meaning and the use of dates future. Forward-looking statements in this press release include statements about our expectation that the marketing campaign will continue to promote increased demand for Lap-Band procedures and, therefore, a potentially significant increase in ReShape’s revenue. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied. – understood by forward-looking statements. These risks and uncertainties are described in greater detail in the Company’s filings with the Securities and Exchange Commission, in particular the factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent quarterly reports. on Form 10-Q. We provide this information as of the date of this press release and undertake no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise, except as required by law. .

CONTACTS:

Company Contact: Thomas Stankovich Chief Financial Officer 949-276-6042 ir@ReShapeLifesci.com

Investor Relations Contact: Rx Communications Group Michael Miller (917)-633-6086 mmiller@rxir.com

A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/73161b8c-9a48-46ce-9314-da10c6ad2adf